

Francisco Escamilla-Sevilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8209900/publications.pdf>

Version: 2024-02-01

32
papers

2,455
citations

471509

17
h-index

377865

34
g-index

39
all docs

39
docs citations

39
times ranked

4009
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study. <i>Brain Sciences</i> , 2022, 12, 383. | 2.3 | 7 |
| 2 | Mutational spectrum of GNAL , THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review. <i>European Journal of Neurology</i> , 2021, 28, 1188-1197. | 3.3 | 2 |
| 3 | Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. <i>Brain Sciences</i> , 2021, 11, 1027. | 2.3 | 6 |
| 4 | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 108. | 5.3 | 8 |
| 5 | Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. <i>Nature Communications</i> , 2021, 12, 7342. | 12.8 | 44 |
| 6 | Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102. | 10.2 | 1,414 |
| 7 | The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863. | 3.9 | 47 |
| 8 | Association of Parkinson's disease and treatment with aminosalicylates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records. <i>BMJ Open</i> , 2019, 9, e025574. | 1.9 | 13 |
| 9 | Validation of a Device for the Ambulatory Monitoring of Sleep Patterns: A Pilot Study on Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 356. | 2.4 | 31 |
| 10 | LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032. | 10.2 | 15 |
| 11 | Inflammatory bowel disease and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 78-79. | 2.2 | 1 |
| 12 | Multidimensional Circadian Monitoring by Wearable Biosensors in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 157. | 2.4 | 37 |
| 13 | Structural genomic variations and Parkinson's disease. <i>Minerva Medica</i> , 2017, 108, 438-447. | 0.9 | 11 |
| 14 | Genome-wide assessment of Parkinson's disease in a Southern Spanish population. <i>Neurobiology of Aging</i> , 2016, 45, 213.e3-213.e9. | 3.1 | 35 |
| 15 | Analysis of the genetic variability in Parkinson's disease from Southern Spain. <i>Neurobiology of Aging</i> , 2016, 37, 210.e1-210.e5. | 3.1 | 23 |
| 16 | Abnormal thermography in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 852-857. | 2.2 | 23 |
| 17 | La dificultad del diagnóstico de mareos y sÃncopes. <i>Revista Clinica Espanola</i> , 2015, 215, 291-292. | 0.6 | 0 |
| 18 | BDNF Val66Met polymorphism in primary adult-onset dystonia: A case-control study and meta-analysis. <i>Movement Disorders</i> , 2014, 29, 1083-1086. | 3.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Posthemorrhagic Hemiparkinsonism Treated by Unilateral Pallidal Stimulation. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 139-141. | 1.5 | 0 |
| 20 | Lack of validation of variants associated with cervical dystonia risk: A GWAS replication study. <i>Movement Disorders</i> , 2014, 29, 1825-1828. | 3.9 | 15 |
| 21 | Neuropsychological Deficits Associated with Destruction of the Right Nigrostriatal Pathway. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 729-734. | 1.8 | 1 |
| 22 | Cognitive Effects of Subthalamic Nucleus Stimulation in Parkinson's Disease: A Controlled Study. <i>European Neurology</i> , 2012, 68, 361-366. | 1.4 | 38 |
| 23 | Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study. <i>Movement Disorders</i> , 2012, 27, 211-218. | 3.9 | 105 |
| 24 | Change of the melanocortin system caused by bilateral subthalamic nucleus stimulation in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 275-281. | 2.1 | 23 |
| 25 | Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 65-69. | 1.9 | 67 |
| 26 | Deep-Brain Stimulation for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2010, 363, 987-988. | 27.0 | 6 |
| 27 | Do α -synuclein aggregates in autonomic plexuses predate Lewy body disorders?. <i>Neurology</i> , 2007, 68, 2012-2018. | 1.1 | 184 |
| 28 | Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 825-831. | 1.9 | 88 |
| 29 | Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 34-39. | 1.9 | 55 |
| 30 | Pallidal vs Subthalamic Deep Brain Stimulation for Parkinson Disease: Winner and Loser or a Sharing of Honors?. <i>Archives of Neurology</i> , 2005, 62, 1642-3; author reply 1643. | 4.5 | 5 |
| 31 | Autotransplantation of Human Carotid Body Cell Aggregates for Treatment of Parkinson's Disease. <i>Neurosurgery</i> , 2003, 53, 321-330. | 1.1 | 99 |
| 32 | Unilateral pallidal stimulation for segmental cervical and truncal dystonia: Which side?. <i>Movement Disorders</i> , 2002, 17, 1383-1385. | 3.9 | 28 |